NovAccess Global is a biomedical company accelerating and investing in novel cancer diagnostics and therapeutics.

WE ARE DEVELOPING

Novel immunotherapeutic approaches to treat brain tumors and neurological diseases

Novel diagnostic tools for earlier and more accurate detection and staging of cancer

AI-based platform and block chain technologies for a more personalized, patient-centered approach to improving the quality of life for cancer and neurological patients

TECHNOLOGY

StemVax Therapeutics, https://stemvax.com, has a novel immunotherapeutic approach to treat brain tumor patients with glioblastoma multiforme, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combines a dendritic cell-based immunotherapeutic approach with a unique combination of Toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient’s tumor.  Our platform technology focuses on enhancing the patient’s immune cells to fight their unique cancer by utilizing the antigens specific to the patient’s tumor. Our unique combination of TLR adjuvants, in addition to the tumor’s antigens, obtained from the patient, promotes an enhanced immune response shown to be more efficacious in pre-clinical studies when compared to previous generations of the therapy. TLR-AD1 therapy is at the Investigational New Drug (IND) filing stage and StemVax Therapeutics seeks to start human clinical trials after obtaining IND approval. 

EXECUTIVE LEADERSHIP

Dwain

Dr. Dwain Irvin

Dr. Irvin is an active participant in many Biotechnology and Health Science endeavors, and is an expert including patent generation in such areas as treatments for Parkinson’s, brain cancer, and even cosmetic application of advanced bioscience. He is also an expert in the physical operations of laboratories, and hospitals. He received his PhD from UCLA School of Medicine, and Masters in Public Health from UCLA School of Public Health, and trained at The Wallenberg Neuroscience Center at Lund University in Lund, Sweden. He was also a Professor, Faculty member at Cedars-Sinai Medical Center, Department of Neurosurgery.

Dr. Irvin’s PhD is in Pharmacology and Developmental Neuroscience with an emphasis on neural stem cell fate and differentiation. His research focused on neural development and Notch Signaling in mammalian neural stem cells. He also worked as an NIH/NINDS Post-Doctoral Fellow in Dr. Anders Bjorklund laboratory in Lund, Sweden. There, his focus was on research projects that investigated the potential role of cell replacement therapy for patients with Parkinson’s disease. They developed several protocols for the efficient generation of dopaminergic neurons from forebrain and ventral midbrain stem and progenitor cells.

Additionally, Dr. Morris-Irvin led research investigations in the role of adaptive immunity in Parkinson’s disease. He also developed two patents in the area of immunotherapy for brain tumor patients, specifically Glioblastoma Multiforme (GBM). His research team focused on molecular mechanisms that impart therapeutic resistance in cancer cells, including cancer stem cells. They utilized this data to develop novel immunotherapies for brain tumor patients.

Dan2

Dan Martin

Mr. Martin is a life-long entrepreneur. Since launching Innovest in 2017, he has turned it into a publicly traded diversified Industrial company that is expected to generate nearly $50 million in gross sales in 2019 and employs over 100 through two segments. He acquired and compressed six companies, turning a company that was worth just $300,000 in 2017 into a company worth over 100 times that amount to start 2019, and debt free at that time. With both successes and failures under his belt, he credits his business tenacity to growing up in his father’s drugstore which required managing very low margins and critically important services, and in conditioning himself to focus on the most important things even when things are chaotic. Mr. Martin has a Bachelors of Science of Business Administration in Finance from John Carroll University.

ADVISORY BOARD

Dan2

Dan Martin

Mr. Martin is a life-long entrepreneur. Since launching Innovest in 2017, he has turned it into a publicly traded diversified Industrial company that is expected to generate nearly $50 million in gross sales in 2019 and employs over 100 through two segments. He acquired and compressed six companies, turning a company that was worth just $300,000 in 2017 into a company worth over 100 times that amount to start 2019, and debt free at that time. With both successes and failures under his belt, he credits his business tenacity to growing up in his father’s drugstore which required managing very low margins and critically important services, and in conditioning himself to focus on the most important things even when things are chaotic. Mr. Martin has a Bachelors of Science of Business Administration in Finance from John Carroll University.